Form 4: BridgeBio Pharma Director Fred Hassan Receives Significant Equity Grant

BridgeBio Pharma, Inc. Director Fred Hassan was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with shareholders through a multi-year vesting schedule.

Summary

• Fred Hassan, a Director of BridgeBio Pharma, Inc. (BBIO), reported an acquisition of equity securities on June 20, 2025.
• The acquisition included 6,589 restricted stock units (RSUs) at a price of $0 per unit.
• Each RSU represents a contingent right to receive one share of BridgeBio Pharma's Common Stock.
• Additionally, Mr. Hassan acquired 8,425 stock options with an exercise price of $41.73 per share.
• Both the RSUs and stock options are granted under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.
• One-third of both the RSUs and the shares underlying the stock options will vest each year after June 20, 2025, with full vesting by June 20, 2028, contingent on Mr. Hassan's continued service on the board of directors.
• Following these transactions, Fred Hassan beneficially owns 25,889 shares of Common Stock directly.
• The stock options have an expiration date of June 19, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a routine compensation event, it signifies continued commitment from a director and aligns their interests with shareholders, which is generally viewed favorably.

Positives

• The equity grants align the director's financial interests directly with the long-term performance and shareholder value of BridgeBio Pharma, Inc.
• The multi-year vesting schedule encourages continued service and commitment from a key board member.

Risks

• The vesting of RSUs and stock options is subject to the reporting person's continued service on the Issuer's board of directors, meaning the benefits are contingent on future engagement.
• The value realized from the stock options is dependent on the future market price of BridgeBio Pharma's common stock exceeding the exercise price of $41.73.

Future Outlook

The vesting schedule for the granted RSUs and stock options extends to June 20, 2028, indicating an expectation of continued service from Director Fred Hassan on the company's board.

Industry Context

Equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain talent while aligning leadership interests with long-term shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to Fred Hassan, a director of BridgeBio Pharma, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to more shareholder-centric decision-making.
• Employees: While not directly impacting employees, the use of equity compensation plans can set a precedent for broader employee incentive structures.

Next Steps

• Fred Hassan's continued service on the BridgeBio Pharma board of directors is required for the vesting of the granted RSUs and stock options.
• The RSUs and stock options will vest in one-third increments annually after June 20, 2025, until fully vested on June 20, 2028.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance, Executive Compensation